MedPath

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Phase 1
Conditions
Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil
Registration Number
NCT00531635
Lead Sponsor
King Faisal Specialist Hospital & Research Center
Brief Summary

Induction of mixed hemopoietic chimerism in patients using Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA \& Mycophenolate Mofetil

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
350
Inclusion Criteria
  • Patients receiving Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil.
Exclusion Criteria
  • Uncontrolled major medical illnesses

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Efficacy2001-2012
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

KFSH&RC

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Β© Copyright 2025. All Rights Reserved by MedPath